(+)-catechin multiple interactions ISO RGD:734157 6480464 [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2C29 mRNA CTD PMID:25663641 (+)-epicatechin-3-O-gallate multiple interactions ISO RGD:734157 6480464 [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2C29 mRNA CTD PMID:25663641 (-)-epigallocatechin 3-gallate multiple interactions ISO RGD:734157 6480464 [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2C29 mRNA CTD PMID:25663641 (R)-lipoic acid multiple interactions ISO RGD:1606589 6480464 Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:24120545 (R,R,R)-alpha-tocopherol multiple interactions ISO RGD:734157 6480464 alpha-Tocopherol inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of CYP2C29 protein] CTD PMID:26102010 1,2-dimethylhydrazine decreases expression ISO RGD:734157 6480464 1, 2-Dimethylhydrazine results in decreased expression of CYP2C29 mRNA CTD PMID:22206623 1,4-naphthoquinone increases abundance ISO RGD:1606589 6480464 CYP2C8 protein results in increased abundance of 1, 4-naphthoquinone CTD PMID:16243959 1-naphthol increases abundance ISO RGD:1606589 6480464 CYP2C8 protein results in increased abundance of 1-naphthol CTD PMID:16243959 14,15-EET increases chemical synthesis ISO RGD:1606589 6480464 CYP2C8 protein results in increased chemical synthesis of 14 more ... CTD PMID:12675279 17alpha-ethynylestradiol decreases activity ISO RGD:1606589 6480464 Ethinyl Estradiol results in decreased activity of CYP2C8 protein CTD PMID:15601807 17beta-estradiol decreases expression ISO RGD:1606589 6480464 Estradiol results in decreased expression of CYP2C8 mRNA CTD PMID:20106945 17beta-estradiol multiple interactions ISO RGD:734157 6480464 fulvestrant inhibits the reaction [Estradiol results in increased expression of CYP2C29 mRNA] CTD PMID:16280380 17beta-estradiol increases expression ISO RGD:734157 6480464 Estradiol results in increased expression of CYP2C29 mRNA CTD PMID:16280380 1H-pyrazole decreases expression ISO RGD:734157 6480464 pyrazole results in decreased expression of CYP2C29 mRNA CTD PMID:17945193 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions ISO RGD:734157 6480464 [Tetrachlorodibenzodioxin co-treated with 2 more ... CTD PMID:28433925 2,2',4,4'-Tetrabromodiphenyl ether affects expression ISO RGD:734157 6480464 2 more ... CTD PMID:30294300 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1606589 6480464 Tetrachlorodibenzodioxin results in decreased expression of CYP2C8 mRNA CTD PMID:20106945 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:734157 6480464 Tetrachlorodibenzodioxin results in decreased expression of CYP2C29 mRNA CTD PMID:28213091 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:734157 6480464 [Tetrachlorodibenzodioxin co-treated with 2 more ... CTD PMID:28433925 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:734157 6480464 Tetrachlorodibenzodioxin results in increased expression of CYP2C29 mRNA CTD PMID:17949056 , PMID:19770486 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of CYP2C79 mRNA CTD PMID:22298810 2,8-bis-Trifluoromethyl-4-quinoline carboxylic acid increases expression ISO RGD:1606589 6480464 Ro 21-5104 results in increased expression of CYP2C8 mRNA CTD PMID:25313206 2-(3,4-dimethoxyphenyl)-5-\{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino\}-2-(propan-2-yl)pentanenitrile decreases activity ISO RGD:1606589 6480464 Verapamil results in decreased activity of CYP2C8 protein CTD PMID:15304522 2-(3,4-dimethoxyphenyl)-5-\{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino\}-2-(propan-2-yl)pentanenitrile decreases activity ISO RGD:734157 6480464 Verapamil results in decreased activity of CYP2C29 protein CTD PMID:18420780 2-(3,4-dimethoxyphenyl)-5-\{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino\}-2-(propan-2-yl)pentanenitrile multiple interactions ISO RGD:1606589 6480464 torsemide inhibits the reaction [Verapamil results in decreased activity of CYP2C8 protein] CTD PMID:15304522 3-methylcholanthrene increases expression ISO RGD:734157 6480464 Methylcholanthrene results in increased expression of CYP2C29 mRNA CTD PMID:30503582 4-[(1E)-1,2-diphenylbut-1-en-1-yl]phenol increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of 1-(4-hydroxyphenyl)-1, 2-diphenyl-1-butene CTD PMID:29285606 4-[(1E)-1,2-diphenylbut-1-en-1-yl]phenol multiple interactions ISO RGD:1606589 6480464 [CYP2C8 protein results in increased metabolism of 1-(4-hydroxyphenyl)-1 more ... CTD PMID:29285606 4-Hydroxy-N-desmethyltamoxifen decreases activity ISO RGD:1606589 6480464 4-hydroxy-N-desmethyltamoxifen results in decreased activity of CYP2C8 protein CTD PMID:29285606 4-hydroxynon-2-enal multiple interactions ISO RGD:734157 6480464 [CYP2C29 protein results in increased oxidation of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 4-hydroxy-2-nonenoic acid more ... CTD PMID:21766881 4-isopropylphenol increases glutathionylation ISO RGD:1606589 6480464 CYP2C8 protein results in increased glutathionylation of 4-isopropylphenol CTD PMID:23470418 5-aza-2'-deoxycytidine increases expression ISO RGD:734157 6480464 Decitabine results in increased expression of CYP2C29 mRNA CTD PMID:30503582 5-methoxyindole decreases activity ISO RGD:734157 6480464 5-methoxyindole results in decreased activity of CYP2C29 protein CTD PMID:18420780 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime affects binding ISO RGD:1606589 6480464 [6-(4-chlorophenyl)imidazo(2 more ... CTD PMID:15933212 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime increases expression ISO RGD:1606589 6480464 6-(4-chlorophenyl)imidazo(2 more ... CTD PMID:15933212 6-hydroxypaclitaxel increases chemical synthesis ISO RGD:1606589 6480464 CYP2C8 protein results in increased chemical synthesis of 6-hydroxytaxol CTD PMID:12401345 6-propyl-2-thiouracil decreases expression EXP 6480464 Propylthiouracil results in decreased expression of CYP2C79 mRNA CTD PMID:24780913 aconitine increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of Aconitine CTD PMID:21277363 aconitine multiple interactions ISO RGD:1606589 6480464 [Gemfibrozil results in decreased activity of CYP2C8 protein] which affects the chemical synthesis of Aconitine metabolite CTD PMID:21277363 acrylamide decreases expression EXP 6480464 Acrylamide results in decreased expression of CYP2C79 mRNA CTD PMID:28959563 afimoxifene increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of afimoxifene CTD PMID:29285606 afimoxifene decreases activity ISO RGD:1606589 6480464 afimoxifene results in decreased activity of CYP2C8 protein CTD PMID:29285606 aflatoxin B1 affects expression ISO RGD:1606589 6480464 Aflatoxin B1 affects the expression of CYP2C8 protein CTD PMID:20106945 aflatoxin B1 decreases methylation ISO RGD:1606589 6480464 Aflatoxin B1 results in decreased methylation of CYP2C8 gene CTD PMID:27153756 aflatoxin B1 decreases expression ISO RGD:1606589 6480464 Aflatoxin B1 results in decreased expression of CYP2C8 mRNA CTD PMID:22100608 , PMID:27153756 all-trans-4-hydroxyretinoic acid increases chemical synthesis ISO RGD:1606589 6480464 CYP2C8 protein results in increased chemical synthesis of 4-hydroxyretinoic acid CTD PMID:10874126 all-trans-4-oxoretinoic acid increases chemical synthesis ISO RGD:1606589 6480464 CYP2C8 protein results in increased chemical synthesis of 4-oxoretinoic acid CTD PMID:10874126 all-trans-retinoic acid affects metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein affects the metabolism of Tretinoin CTD PMID:15933212 all-trans-retinoic acid increases hydroxylation ISO RGD:1606589 6480464 CYP2C8 protein results in increased hydroxylation of Tretinoin CTD PMID:10874126 all-trans-retinoic acid decreases activity ISO RGD:734157 6480464 Tretinoin results in decreased activity of CYP2C29 protein CTD PMID:18420780 all-trans-retinoic acid increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of Tretinoin CTD PMID:12464242 almotriptan decreases methylation ISO RGD:1606589 6480464 CYP2C8 protein results in decreased methylation of almotriptan CTD PMID:12642466 aminophenazone multiple interactions ISO RGD:1606589 6480464 Amoxicillin inhibits the reaction [CYP2C8 protein results in decreased methylation of Aminopyrine], Piperacillin inhibits the reaction [CYP2C8 protein results in decreased methylation of Aminopyrine] CTD PMID:26763401 aminophenazone decreases methylation ISO RGD:1606589 6480464 CYP2C8 protein results in decreased methylation of Aminopyrine CTD PMID:26763401 amiodarone decreases activity ISO RGD:1606589 6480464 Amiodarone results in decreased activity of CYP2C8 protein CTD PMID:15304522 amiodarone decreases response to substance ISO RGD:1606589 6480464 CYP2C8 protein results in decreased susceptibility to Amiodarone CTD PMID:26477383 amiodarone multiple interactions ISO RGD:1606589 6480464 torsemide inhibits the reaction [Amiodarone results in decreased activity of CYP2C8 protein] CTD PMID:15304522 amiodarone increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of Amiodarone CTD PMID:15716363 amodiaquine multiple interactions ISO RGD:1606589 6480464 [5-bromotryptamine analog results in decreased activity of CYP2C8 protein] which results in decreased metabolism of Amodiaquine more ... CTD PMID:15771232 more ... amodiaquine increases response to substance ISO RGD:1606589 6480464 CYP2C8 protein results in increased susceptibility to Amodiaquine CTD PMID:31629065 amodiaquine increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of Amodiaquine CTD PMID:15155557 more ... amodiaquine affects metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein affects the metabolism of Amodiaquine CTD PMID:12920490 , PMID:15626586 amoxicillin multiple interactions ISO RGD:1606589 6480464 Amoxicillin inhibits the reaction [CYP2C8 protein results in decreased methylation of Aminopyrine] CTD PMID:26763401 amoxicillin decreases activity ISO RGD:1606589 6480464 Amoxicillin results in decreased activity of CYP2C8 protein CTD PMID:26763401 arachidonic acid increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of Arachidonic Acid CTD PMID:12675279 Aroclor 1254 increases expression ISO RGD:1606589 6480464 Chlorodiphenyl (54% Chlorine) results in increased expression of CYP2C8 mRNA CTD PMID:17851650 Aroclor 1254 increases expression ISO RGD:734157 6480464 Chlorodiphenyl (54% Chlorine) results in increased expression of CYP2C29 mRNA CTD PMID:25270620 atrazine multiple interactions ISO RGD:734157 6480464 [Endosulfan co-treated with Atrazine co-treated with Chlorpyrifos] results in increased expression of CYP2C29 mRNA CTD PMID:22515965 Auriculasin increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of auriculasin CTD PMID:31515991 Auriculasin multiple interactions ISO RGD:1606589 6480464 Quercetin inhibits the reaction [CYP2C8 protein results in increased metabolism of auriculasin] CTD PMID:31515991 benzo[a]pyrene increases expression ISO RGD:734157 6480464 Benzo(a)pyrene results in increased expression of CYP2C29 mRNA, Benzo(a)pyrene results in increased expression of CYP2C29 protein CTD PMID:19770486 more ... benzo[a]pyrene decreases expression ISO RGD:1606589 6480464 Benzo(a)pyrene results in decreased expression of CYP2C8 mRNA CTD PMID:32234424 beta-hexachlorocyclohexane increases expression ISO RGD:734157 6480464 beta-hexachlorocyclohexane results in increased expression of CYP2C29 mRNA CTD PMID:25270620 bezafibrate decreases expression ISO RGD:1606589 6480464 Bezafibrate results in decreased expression of CYP2C8 protein CTD PMID:29960002 bifenthrin increases expression ISO RGD:734157 6480464 bifenthrin results in increased expression of CYP2C29 mRNA CTD PMID:26071804 bis(2-ethylhexyl) phthalate increases expression ISO RGD:734157 6480464 Diethylhexyl Phthalate results in increased expression of CYP2C29 mRNA CTD PMID:19245819 , PMID:19850644 bis(2-ethylhexyl) phthalate multiple interactions ISO RGD:734157 6480464 [Tetrachlorodibenzodioxin co-treated with 2 more ... CTD PMID:19850644 , PMID:28433925 bisphenol A increases hydroxylation ISO RGD:1606589 6480464 CYP2C8 protein results in increased hydroxylation of bisphenol A, CYP2C8 protein results in increased hydroxylation of bisphenol A metabolite CTD PMID:23470418 bisphenol A increases expression ISO RGD:734157 6480464 bisphenol A results in increased expression of CYP2C29 mRNA CTD PMID:30245210 , PMID:33221593 bisphenol A multiple interactions ISO RGD:734157 6480464 [Tetrachlorodibenzodioxin co-treated with 2 more ... CTD PMID:28433925 bisphenol A decreases activity ISO RGD:1606589 6480464 bisphenol A results in decreased activity of CYP2C8 protein CTD PMID:10784435 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of CYP2C8 mRNA CTD PMID:25181051 bisphenol A increases glutathionylation ISO RGD:1606589 6480464 CYP2C8 protein results in increased glutathionylation of bisphenol A, CYP2C8 protein results in increased glutathionylation of bisphenol A metabolite CTD PMID:23470418 bisphenol F increases glutathionylation ISO RGD:1606589 6480464 CYP2C8 protein results in increased glutathionylation of 4, 4'-bisphenol F CTD PMID:23470418 bisphenol F increases hydroxylation ISO RGD:1606589 6480464 CYP2C8 protein results in increased hydroxylation of 4, 4'-bisphenol F CTD PMID:23470418 bromfenac increases hydroxylation ISO RGD:1606589 6480464 CYP2C8 protein results in increased hydroxylation of bromfenac CTD PMID:31815452 Bufuralol increases hydroxylation ISO RGD:1606589 6480464 CYP2C8 protein results in increased hydroxylation of bufuralol CTD PMID:9429232 buprenorphine affects metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein affects the metabolism of Buprenorphine CTD PMID:16010532 buta-1,3-diene decreases expression ISO RGD:734157 6480464 1, 3-butadiene results in decreased expression of CYP2C29 mRNA CTD PMID:29038090 butyric acid increases expression ISO RGD:1606589 6480464 Butyric Acid results in increased expression of CYP2C8 mRNA CTD PMID:30439556 calciol decreases activity ISO RGD:734157 6480464 Cholecalciferol results in decreased activity of CYP2C29 protein CTD PMID:18420780 camptothecin decreases expression ISO RGD:1606589 6480464 Camptothecin results in decreased expression of CYP2C8 mRNA CTD PMID:29356861 camptothecin multiple interactions ISO RGD:1606589 6480464 Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA] CTD PMID:29356861 Candesartan cilexetil decreases activity ISO RGD:1606589 6480464 candesartan cilexetil results in decreased activity of CYP2C8 protein CTD PMID:15601807 cannabidiol multiple interactions ISO RGD:734157 6480464 [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CYP2C29 mRNA CTD PMID:33096940 captan multiple interactions ISO RGD:734157 6480464 [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2C29 mRNA CTD PMID:32745781 captan increases expression ISO RGD:734157 6480464 Captan results in increased expression of CYP2C29 mRNA CTD PMID:31558096 carbamazepine increases expression ISO RGD:1606589 6480464 Carbamazepine results in increased expression of CYP2C8 mRNA CTD PMID:17112801 carbamazepine affects metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein affects the metabolism of Carbamazepine CTD PMID:15286053 , PMID:15915352 carbamazepine increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of Carbamazepine CTD PMID:12464242 carbamazepine multiple interactions ISO RGD:1606589 6480464 Probenecid promotes the reaction [CYP2C8 protein affects the metabolism of Carbamazepine] CTD PMID:15915352 carbamazepine-10,11-epoxide multiple interactions ISO RGD:1606589 6480464 Probenecid promotes the reaction [CYP2C8 protein affects the chemical synthesis of carbamazepine epoxide] CTD PMID:15915352 carbamazepine-10,11-epoxide affects chemical synthesis ISO RGD:1606589 6480464 CYP2C8 protein affects the chemical synthesis of carbamazepine epoxide CTD PMID:15915352 carfentanil increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of carfentanil CTD PMID:33652071 cerivastatin affects response to substance ISO RGD:1606589 6480464 CYP2C8 gene mutant form affects the susceptibility to cerivastatin CTD PMID:15365880 cerivastatin increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of cerivastatin CTD PMID:12464242 more ... chenodeoxycholic acid decreases expression ISO RGD:1606589 6480464 Chenodeoxycholic Acid results in decreased expression of CYP2C8 mRNA CTD PMID:27174168 chenodeoxycholic acid multiple interactions ISO RGD:1606589 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C8 mRNA, [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C8 mRNA CTD PMID:33819548 chloroquine affects metabolic processing ISO RGD:1606589 6480464 CYP2C8 polymorphism affects the metabolism of Chloroquine, CYP2C8 protein affects the metabolism of Chloroquine CTD PMID:12920490 , PMID:19560616 chloroquine multiple interactions ISO RGD:1606589 6480464 [CYP2C8 protein results in increased metabolism of Chloroquine] which results in increased abundance of desethylchloroquine, Quercetin inhibits the reaction [[CYP2C8 protein results in increased metabolism of Chloroquine] which results in increased abundance of desethylchloroquine] CTD PMID:12756207 , PMID:12967198 chloroquine increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of Chloroquine CTD PMID:17286541 chlorpromazine decreases response to substance ISO RGD:1606589 6480464 CYP2C8 protein results in decreased susceptibility to Chlorpromazine CTD PMID:26477383 chlorpyrifos multiple interactions ISO RGD:734157 6480464 [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2C29 mRNA more ... CTD PMID:22515965 more ... choline multiple interactions ISO RGD:734157 6480464 [LEP gene mutant form results in increased susceptibility to [Methionine co-treated with Choline]] which results in decreased expression of CYP2C29 mRNA more ... CTD PMID:22872676 , PMID:27712037 cinitapride increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of cinitapride CTD PMID:17437965 ciprofibrate decreases expression ISO RGD:734157 6480464 ciprofibrate results in decreased expression of CYP2C29 mRNA CTD PMID:12771043 clofibric acid increases activity ISO RGD:1606589 6480464 Clofibric Acid results in increased activity of CYP2C8 protein CTD PMID:15771232 clofibric acid increases expression ISO RGD:1606589 6480464 Clofibric Acid results in increased expression of CYP2C8 mRNA, Clofibric Acid results in increased expression of CYP2C8 protein CTD PMID:15771232 Clofop increases activity ISO RGD:1606589 6480464 fenofibric acid results in increased activity of CYP2C8 protein CTD PMID:15771232 Clofop increases expression ISO RGD:1606589 6480464 fenofibric acid results in increased expression of CYP2C8 mRNA, fenofibric acid results in increased expression of CYP2C8 protein CTD PMID:15771232 clopidogrel multiple interactions ISO RGD:1606589 6480464 CYP2C8 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite CTD PMID:19170597 clotrimazole decreases activity ISO RGD:1606589 6480464 Clotrimazole results in decreased activity of CYP2C8 protein CTD PMID:15601807 , PMID:33775687 clozapine increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of Clozapine CTD PMID:18809730 , PMID:27320963 Clozapine N-oxide increases abundance ISO RGD:1606589 6480464 CYP2C8 protein results in increased abundance of clozapine N-oxide CTD PMID:27320963 cobalt atom increases expression ISO RGD:734157 6480464 Cobalt results in increased expression of CYP2C29 mRNA CTD PMID:22147119 cobalt dichloride decreases expression ISO RGD:734157 6480464 cobaltous chloride results in decreased expression of CYP2C protein, cobaltous chloride results in decreased expression of CYP2C29 mRNA CTD PMID:12051692 , PMID:23528251 cocaine decreases expression ISO RGD:1606589 6480464 Cocaine results in decreased expression of CYP2C8 mRNA, Cocaine results in decreased expression of CYP2C8 protein CTD PMID:16188404 cumene hydroperoxide affects oxidation ISO RGD:1606589 6480464 CYP2C8 protein affects the oxidation of cumene hydroperoxide CTD PMID:17478480 cyclophosphamide increases activity ISO RGD:1606589 6480464 CYP2C8 results in increased activity of Cyclophosphamide CTD PMID:9241661 cyclophosphamide increases expression ISO RGD:734157 6480464 Cyclophosphamide results in increased expression of CYP2C29 mRNA CTD PMID:24819615 cyclosporin A decreases expression ISO RGD:1606589 6480464 Cyclosporine results in decreased expression of CYP2C8 mRNA CTD PMID:20106945 cyclosporin A decreases expression ISO RGD:734157 6480464 Cyclosporine results in decreased expression of CYP2C29 mRNA CTD PMID:19770486 cyclosporin A affects oxidation ISO RGD:1606589 6480464 CYP2C8 protein affects the oxidation of Cyclosporine CTD PMID:7870052 cylindrospermopsin decreases expression ISO RGD:1606589 6480464 cylindrospermopsin results in decreased expression of CYP2C8 mRNA CTD PMID:30905859 cylindrospermopsin decreases expression ISO RGD:734157 6480464 cylindrospermopsin results in decreased expression of CYP2C29 mRNA CTD PMID:20936652 cypermethrin increases expression ISO RGD:1606589 6480464 cypermethrin results in increased expression of CYP2C8 mRNA CTD PMID:22310298 cypermethrin decreases activity ISO RGD:734157 6480464 cypermethrin results in decreased activity of CYP2C29 protein CTD PMID:18420780 cyproconazole increases expression ISO RGD:734157 6480464 cyproconazole results in increased expression of CYP2C29 protein CTD PMID:33150952 dabrafenib decreases activity ISO RGD:1606589 6480464 dabrafenib results in decreased activity of CYP2C8 protein CTD PMID:34780725 daidzein decreases activity ISO RGD:734157 6480464 daidzein results in decreased activity of CYP2C29 protein CTD PMID:18420780 dapsone increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of Dapsone CTD PMID:17286541 deoxycholic acid multiple interactions ISO RGD:1606589 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C8 mRNA, [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C8 mRNA CTD PMID:33819548 Desethylchloroquine multiple interactions ISO RGD:1606589 6480464 [CYP2C8 protein results in increased metabolism of Chloroquine] which results in increased abundance of desethylchloroquine, Quercetin inhibits the reaction [[CYP2C8 protein results in increased metabolism of Chloroquine] which results in increased abundance of desethylchloroquine] CTD PMID:12756207 , PMID:12967198 dexamethasone affects binding ISO RGD:1606589 6480464 [Dexamethasone binds to NR3C1 protein] which binds to CYP2C8 promoter CTD PMID:15933212 dexamethasone increases expression ISO RGD:1606589 6480464 Dexamethasone results in increased expression of CYP2C8 mRNA CTD PMID:15933212 , PMID:19118567 dextran sulfate multiple interactions ISO RGD:734157 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C29 mRNA CTD PMID:29950665 dichloroacetic acid decreases expression ISO RGD:734157 6480464 Dichloroacetic Acid results in decreased expression of CYP2C29 mRNA CTD PMID:28962523 dichloromethane affects expression ISO RGD:734157 6480464 Methylene Chloride affects the expression of CYP2C29 mRNA CTD PMID:28392392 diclofenac decreases activity ISO RGD:734157 6480464 Diclofenac results in decreased activity of CYP2C29 protein CTD PMID:18420780 dihydroergotamine decreases activity ISO RGD:734157 6480464 Dihydroergotamine results in decreased activity of CYP2C29 protein CTD PMID:18420780 Dihydrotanshinone I decreases activity ISO RGD:1606589 6480464 dihydrotanshinone I results in decreased activity of CYP2C8 protein CTD PMID:29689254 diosmetin decreases activity ISO RGD:1606589 6480464 diosmetin results in decreased activity of CYP2C8 protein CTD PMID:28867436 domperidone increases hydroxylation ISO RGD:1606589 6480464 CYP2C8 protein results in increased hydroxylation of Domperidone CTD PMID:15327587 dopamine decreases activity ISO RGD:734157 6480464 Dopamine results in decreased activity of CYP2C29 protein CTD PMID:18420780 endosulfan multiple interactions ISO RGD:734157 6480464 [Endosulfan co-treated with Atrazine co-treated with Chlorpyrifos] results in increased expression of CYP2C29 mRNA CTD PMID:22515965 endosulfan increases expression ISO RGD:734157 6480464 Endosulfan analog results in increased expression of CYP2C29 mRNA, Endosulfan results in increased expression of CYP2C29 mRNA CTD PMID:22515965 , PMID:29702342 erythromycin A decreases activity ISO RGD:734157 6480464 Erythromycin results in decreased activity of CYP2C29 protein CTD PMID:18420780 etoposide increases expression ISO RGD:734157 6480464 Etoposide results in increased expression of CYP2C29 mRNA CTD PMID:25270620 felbamate increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of Felbamate CTD PMID:35786679 felodipine decreases activity ISO RGD:1606589 6480464 Felodipine results in decreased activity of CYP2C8 protein CTD PMID:15601807 , PMID:28119166 felodipine multiple interactions ISO RGD:1606589 6480464 Felodipine inhibits the reaction [CYP2C8 protein results in increased metabolism of Amodiaquine] CTD PMID:28119166 fenitrothion decreases activity ISO RGD:1606589 6480464 Fenitrothion results in decreased activity of CYP2C8 protein CTD PMID:20183062 fenofibrate decreases activity ISO RGD:1606589 6480464 Fenofibrate results in decreased activity of CYP2C8 protein CTD PMID:15601807 fenofibrate affects expression ISO RGD:1606589 6480464 Fenofibrate affects the expression of CYP2C8 protein CTD PMID:29960002 fenofibrate increases expression ISO RGD:1606589 6480464 Fenofibrate results in increased expression of CYP2C8 mRNA CTD PMID:25572481 fenvalerate increases expression ISO RGD:1606589 6480464 fenvalerate results in increased expression of CYP2C8 mRNA CTD PMID:22310298 fipronil increases expression ISO RGD:1606589 6480464 fipronil results in increased expression of CYP2C8 mRNA CTD PMID:27091632 fipronil increases expression ISO RGD:734157 6480464 fipronil results in increased expression of CYP2C29 mRNA CTD PMID:23962444 fipronil multiple interactions ISO RGD:1606589 6480464 [fipronil co-treated with DEET] results in increased expression of CYP2C8 mRNA CTD PMID:27091632 fluconazole increases expression ISO RGD:734157 6480464 Fluconazole results in increased expression of CYP2C29 mRNA CTD PMID:16730040 fluoxetine decreases activity ISO RGD:1606589 6480464 Fluoxetine results in decreased activity of CYP2C8 protein CTD PMID:15304522 fluoxetine multiple interactions ISO RGD:1606589 6480464 torsemide inhibits the reaction [Fluoxetine results in decreased activity of CYP2C8 protein] CTD PMID:15304522 folic acid multiple interactions ISO RGD:734157 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of CYP2C29 mRNA CTD PMID:22872676 fructose multiple interactions ISO RGD:734157 6480464 [Dietary Fats co-treated with Fructose] results in increased expression of CYP2C29 mRNA more ... CTD PMID:26102010 fulvestrant multiple interactions ISO RGD:734157 6480464 fulvestrant inhibits the reaction [Estradiol results in increased expression of CYP2C29 mRNA], fulvestrant inhibits the reaction [Methoxychlor results in increased expression of CYP2C29 mRNA] CTD PMID:16280380 fumonisin B1 decreases expression ISO RGD:734157 6480464 fumonisin B1 results in decreased expression of CYP2C29 mRNA CTD PMID:16221962 furan decreases expression EXP 6480464 furan results in decreased expression of CYP2C79 mRNA CTD PMID:26194646 furan decreases expression ISO RGD:734157 6480464 furan results in decreased expression of CYP2C29 mRNA CTD PMID:20194422 gallocatechin multiple interactions ISO RGD:734157 6480464 [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2C29 mRNA CTD PMID:25663641 gemfibrozil multiple interactions ISO RGD:1606589 6480464 [Gemfibrozil co-treated with Amodiaquine] results in decreased activity of CYP2C8 protein more ... CTD PMID:15771232 more ... gemfibrozil increases expression ISO RGD:1606589 6480464 Gemfibrozil results in increased expression of CYP2C8 mRNA CTD PMID:15771232 gemfibrozil decreases expression ISO RGD:1606589 6480464 Gemfibrozil results in decreased expression of CYP2C8 protein CTD PMID:15771232 , PMID:29960002 gemfibrozil decreases activity ISO RGD:1606589 6480464 Gemfibrozil metabolite results in decreased activity of CYP2C8 protein, Gemfibrozil results in decreased activity of CYP2C8 protein CTD PMID:15771232 , PMID:16042675 genistein increases expression ISO RGD:734157 6480464 Genistein results in increased expression of CYP2C29 mRNA CTD PMID:32186404 glutathione multiple interactions ISO RGD:1606589 6480464 [CYP2C8 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased abundance of 2'-(glutathion-S-yl)-deschlorodiclofenac CTD PMID:24246759 glycochenodeoxycholic acid multiple interactions ISO RGD:1606589 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C8 mRNA, [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C8 mRNA CTD PMID:33819548 glycocholic acid multiple interactions ISO RGD:1606589 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C8 mRNA, [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C8 mRNA CTD PMID:33819548 glycodeoxycholic acid multiple interactions ISO RGD:1606589 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C8 mRNA, [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C8 mRNA CTD PMID:33819548 glyoxal multiple interactions ISO RGD:1606589 6480464 [CYP2C8 protein results in increased metabolism of and results in increased susceptibility to sudoxicam] which results in increased chemical synthesis of Glyoxal CTD PMID:33253783 griseofulvin affects expression ISO RGD:734157 6480464 Griseofulvin affects the expression of CYP2C29 mRNA CTD PMID:12735108 Heptachlor epoxide increases expression ISO RGD:734157 6480464 Heptachlor Epoxide results in increased expression of CYP2C29 mRNA CTD PMID:25270620 Hypaconitine increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of hypaconitine CTD PMID:21550385 ibuprofen affects metabolic processing ISO RGD:1606589 6480464 CYP2C8 gene polymorphism affects the metabolism of Ibuprofen CTD PMID:15606441 ibuprofen increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 gene polymorphism results in increased metabolism of Ibuprofen CTD PMID:18694831 ibuprofen decreases metabolic processing ISO RGD:1606589 6480464 CYP2C8 gene polymorphism results in decreased metabolism of Ibuprofen CTD PMID:15289789 ifosfamide increases activity ISO RGD:1606589 6480464 CYP2C8 results in increased activity of Ifosfamide CTD PMID:9241661 irbesartan decreases activity ISO RGD:1606589 6480464 irbesartan results in decreased activity of CYP2C8 protein CTD PMID:15601807 isoniazide decreases activity ISO RGD:1606589 6480464 Isoniazid results in decreased activity of CYP2C8 protein CTD PMID:15304522 isoniazide multiple interactions ISO RGD:1606589 6480464 torsemide inhibits the reaction [Isoniazid results in decreased activity of CYP2C8 protein] CTD PMID:15304522 isoproturon decreases activity ISO RGD:734157 6480464 isoproturon results in decreased activity of CYP2C29 protein CTD PMID:18420780 ivermectin decreases activity ISO RGD:734157 6480464 Ivermectin results in decreased activity of CYP2C29 protein CTD PMID:18420780 ketoconazole decreases activity ISO RGD:1606589 6480464 Ketoconazole results in decreased activity of CYP2C8 protein CTD PMID:14709627 , PMID:15601807 ketoconazole decreases activity ISO RGD:734157 6480464 Ketoconazole results in decreased activity of CYP2C29 protein CTD PMID:18420780 ketoconazole multiple interactions ISO RGD:1606589 6480464 Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:24120545 L-methionine multiple interactions ISO RGD:734157 6480464 [LEP gene mutant form results in increased susceptibility to [Methionine co-treated with Choline]] which results in decreased expression of CYP2C29 mRNA more ... CTD PMID:22872676 , PMID:27712037 lansoprazole affects metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein affects the metabolism of Lansoprazole CTD PMID:7870052 lansoprazole increases hydroxylation ISO RGD:1606589 6480464 CYP2C8 protein results in increased hydroxylation of Lansoprazole CTD PMID:8627562 Licochalcone A decreases activity ISO RGD:1606589 6480464 licochalcone A results in decreased activity of CYP2C8 protein CTD PMID:26100226 lipoic acid multiple interactions ISO RGD:1606589 6480464 Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:24120545 lipopolysaccharide multiple interactions ISO RGD:734157 6480464 Lipopolysaccharides inhibits the reaction [1 more ... CTD PMID:22466549 lithocholic acid decreases activity ISO RGD:734157 6480464 Lithocholic Acid results in decreased activity of CYP2C29 protein CTD PMID:18420780 loratadine decreases activity ISO RGD:1606589 6480464 Loratadine results in decreased activity of CYP2C8 protein CTD PMID:15601807 lovastatin decreases activity ISO RGD:1606589 6480464 Lovastatin results in decreased activity of CYP2C8 protein CTD PMID:15601807 medroxyprogesterone decreases activity ISO RGD:1606589 6480464 Medroxyprogesterone results in decreased activity of CYP2C8 protein CTD PMID:15601807 MeIQx decreases expression ISO RGD:1606589 6480464 2-amino-3 more ... CTD PMID:20816883 mephenytoin decreases activity ISO RGD:734157 6480464 Mephenytoin results in decreased activity of CYP2C29 protein CTD PMID:18420780 mercury dichloride increases expression ISO RGD:734157 6480464 Mercuric Chloride results in increased expression of CYP2C29 mRNA CTD PMID:24472606 methidathion increases expression ISO RGD:734157 6480464 methidathion results in increased expression of CYP2C29 mRNA CTD PMID:34813904 methoxsalen decreases activity ISO RGD:734157 6480464 Methoxsalen results in decreased activity of CYP2C29 protein CTD PMID:18420780 methoxychlor decreases methylation ISO RGD:1606589 6480464 CYP2C8 protein results in decreased methylation of Methoxychlor CTD PMID:12167570 , PMID:12433799 methoxychlor increases expression ISO RGD:734157 6480464 Methoxychlor results in increased expression of CYP2C29 mRNA CTD PMID:16280380 , PMID:21252393 methoxychlor multiple interactions ISO RGD:734157 6480464 ESR1 protein promotes the reaction [Methoxychlor results in increased expression of CYP2C29 mRNA], fulvestrant inhibits the reaction [Methoxychlor results in increased expression of CYP2C29 mRNA] CTD PMID:16280380 , PMID:21252393 methoxychlor decreases activity ISO RGD:734157 6480464 Methoxychlor results in decreased activity of CYP2C29 protein CTD PMID:18420780 methyltestosterone multiple interactions ISO RGD:1606589 6480464 [Methyltestosterone co-treated with Cholic Acids] affects the expression of CYP2C8 mRNA CTD PMID:27344345 midazolam decreases activity ISO RGD:734157 6480464 Midazolam results in decreased activity of CYP2C29 protein CTD PMID:18420780 mometasone furoate decreases activity ISO RGD:1606589 6480464 Mometasone Furoate results in decreased activity of CYP2C8 protein CTD PMID:15601807 monosodium L-glutamate increases expression ISO RGD:734157 6480464 Sodium Glutamate results in increased expression of CYP2C29 mRNA CTD PMID:20111022 monosodium L-glutamate multiple interactions ISO RGD:734157 6480464 [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2C29 mRNA CTD PMID:25663641 montelukast decreases activity ISO RGD:1606589 6480464 montelukast results in decreased activity of CYP2C8 protein CTD PMID:15601807 more ... montelukast increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of montelukast CTD PMID:19309152 mycophenolic acid increases methylation ISO RGD:1606589 6480464 CYP2C8 protein results in increased methylation of Mycophenolic Acid CTD PMID:15570183 N,N-diethyl-m-toluamide increases expression ISO RGD:1606589 6480464 DEET results in increased expression of CYP2C8 mRNA CTD PMID:27091632 N,N-diethyl-m-toluamide multiple interactions ISO RGD:1606589 6480464 [fipronil co-treated with DEET] results in increased expression of CYP2C8 mRNA CTD PMID:27091632 N-desmethylclozapine increases chemical synthesis ISO RGD:1606589 6480464 CYP2C8 protein results in increased chemical synthesis of norclozapine CTD PMID:18809730 N-nitrosodiethylamine decreases expression ISO RGD:734157 6480464 Diethylnitrosamine results in decreased expression of CYP2C29 mRNA CTD PMID:12771043 NADP zwitterion multiple interactions ISO RGD:1606589 6480464 [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid more ... CTD PMID:24120545 NADP(+) multiple interactions ISO RGD:1606589 6480464 [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid more ... CTD PMID:24120545 naphthalene increases expression ISO RGD:1606589 6480464 naphthalene results in increased expression of CYP2C8 mRNA CTD PMID:20500019 Neferine multiple interactions ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of and results in decreased methylation of neferine CTD PMID:25451576 Neferine increases glutathionylation ISO RGD:1606589 6480464 CYP2C8 protein results in increased glutathionylation of neferine metabolite CTD PMID:25451576 nicardipine affects metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein affects the metabolism of Nicardipine CTD PMID:15863898 nicardipine decreases activity ISO RGD:1606589 6480464 Nicardipine results in decreased activity of CYP2C8 protein CTD PMID:15863898 nifedipine decreases activity ISO RGD:1606589 6480464 Nifedipine results in decreased activity of CYP2C8 protein CTD PMID:15601807 nifedipine decreases activity ISO RGD:734157 6480464 Nifedipine results in decreased activity of CYP2C29 protein CTD PMID:18420780 Nonylphenol increases expression ISO RGD:734157 6480464 nonylphenol results in increased expression of CYP2C29 mRNA CTD PMID:19041682 Nonylphenol multiple interactions ISO RGD:734157 6480464 NR1I3 gene mutant form affects the reaction [nonylphenol results in increased expression of CYP2C29 mRNA] CTD PMID:19041682 nortriptyline decreases activity ISO RGD:1606589 6480464 Nortriptyline results in decreased activity of CYP2C8 protein CTD PMID:15304522 nortriptyline multiple interactions ISO RGD:1606589 6480464 torsemide inhibits the reaction [Nortriptyline results in decreased activity of CYP2C8 protein] CTD PMID:15304522 O-methyleugenol decreases expression ISO RGD:1606589 6480464 methyleugenol results in decreased expression of CYP2C8 mRNA CTD PMID:32234424 obeticholic acid decreases expression ISO RGD:1606589 6480464 obeticholic acid results in decreased expression of CYP2C8 mRNA CTD PMID:27939613 okadaic acid decreases expression ISO RGD:734157 6480464 Okadaic Acid results in decreased expression of CYP2C29 mRNA CTD PMID:25270620 ortho-Aminoazotoluene multiple interactions ISO RGD:734157 6480464 NR1I3 gene mutant form inhibits the reaction [o-Aminoazotoluene results in increased expression of CYP2C29 mRNA] CTD PMID:21672546 ortho-Aminoazotoluene increases expression ISO RGD:734157 6480464 o-Aminoazotoluene results in increased expression of CYP2C29 mRNA CTD PMID:21672546 oxybutynin decreases activity ISO RGD:1606589 6480464 oxybutynin results in decreased activity of CYP2C8 protein CTD PMID:15601807 ozone decreases expression ISO RGD:734157 6480464 Ozone results in decreased expression of CYP2C29 mRNA CTD PMID:16183385 p-menthan-3-ol increases expression ISO RGD:734157 6480464 Menthol results in increased expression of CYP2C29 mRNA CTD PMID:24594507 paclitaxel increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of Paclitaxel CTD PMID:12401345 more ... paclitaxel increases response to substance ISO RGD:1606589 6480464 CYP2C8 mRNA results in increased susceptibility to Paclitaxel CTD PMID:15239142 paclitaxel increases hydroxylation ISO RGD:1606589 6480464 CYP2C8 protein results in increased hydroxylation of Paclitaxel CTD PMID:21964418 paclitaxel affects metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein affects the metabolism of Paclitaxel CTD PMID:15901749 , PMID:15933212 paclitaxel affects response to substance ISO RGD:1606589 6480464 CYP2C8 gene SNP affects the susceptibility to Paclitaxel CTD PMID:27736846 paclitaxel increases oxidation ISO RGD:1606589 6480464 CYP2C8 protein results in increased oxidation of Paclitaxel CTD PMID:17478480 paclitaxel multiple interactions ISO RGD:1606589 6480464 Cyclohexenes analog inhibits the reaction [CYP2C8 protein results in increased metabolism of Paclitaxel] more ... CTD PMID:20452209 more ... paracetamol affects expression ISO RGD:734157 6480464 Acetaminophen affects the expression of CYP2C29 mRNA CTD PMID:17562736 paracetamol multiple interactions ISO RGD:1606589 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C8 mRNA CTD PMID:33819548 paracetamol decreases expression ISO RGD:1606589 6480464 Acetaminophen results in decreased expression of CYP2C8 mRNA CTD PMID:29067470 parathion affects metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein affects the metabolism of Parathion CTD PMID:12669189 parathion increases expression ISO RGD:734157 6480464 Parathion results in increased expression of CYP2C29 mRNA CTD PMID:34813904 pazopanib increases expression ISO RGD:1606589 6480464 pazopanib results in increased expression of CYP2C8 mRNA CTD PMID:29356861 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:1606589 6480464 perfluorooctane sulfonic acid inhibits the reaction [CYP2C8 protein results in increased hydroxylation of Paclitaxel] CTD PMID:21964418 perfluorooctane-1-sulfonic acid increases expression ISO RGD:734157 6480464 perfluorooctane sulfonic acid results in increased expression of CYP2C29 protein CTD PMID:32979393 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:734157 6480464 [Dietary Fats co-treated with perfluorooctane sulfonic acid] results in increased expression of CYP2C29 mRNA more ... CTD PMID:32979393 more ... perfluorooctane-1-sulfonic acid increases expression ISO RGD:1606589 6480464 perfluorooctane sulfonic acid results in increased expression of CYP2C8 mRNA CTD PMID:27153767 , PMID:32588087 perfluorooctanoic acid affects expression ISO RGD:734157 6480464 perfluorooctanoic acid affects the expression of CYP2C29 mRNA CTD PMID:18281256 perfluorooctanoic acid increases expression ISO RGD:734157 6480464 perfluorooctanoic acid results in increased expression of CYP2C29 mRNA CTD PMID:23626681 perfluorooctanoic acid decreases expression ISO RGD:734157 6480464 perfluorooctanoic acid results in decreased expression of CYP2C29 mRNA CTD PMID:18467677 perfluorooctanoic acid multiple interactions ISO RGD:734157 6480464 [perfluorooctanoic acid co-treated with Dietary Fats more ... CTD PMID:18467677 , PMID:23626681 phencyclidine affects metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein affects the metabolism of Phencyclidine CTD PMID:16782764 Phenelzine multiple interactions ISO RGD:1606589 6480464 torsemide inhibits the reaction [Phenelzine results in decreased activity of CYP2C8 protein] CTD PMID:15304522 Phenelzine decreases activity ISO RGD:1606589 6480464 Phenelzine results in decreased activity of CYP2C8 protein CTD PMID:15304522 phenobarbital increases expression ISO RGD:1606589 6480464 Phenobarbital results in increased expression of CYP2C29 protein, Phenobarbital results in increased expression of CYP2C8 mRNA CTD PMID:19118567 more ... phenobarbital affects expression ISO RGD:734157 6480464 Phenobarbital affects the expression of CYP2C29 mRNA CTD PMID:23091169 phenobarbital multiple interactions ISO RGD:734157 6480464 NR1I3 protein affects the reaction [Phenobarbital results in increased expression of CYP2C29 mRNA] CTD PMID:19482888 phenobarbital increases expression ISO RGD:734157 6480464 Phenobarbital results in increased expression of CYP2C protein more ... CTD PMID:12051692 more ... phenytoin affects expression ISO RGD:734157 6480464 Phenytoin affects the expression of CYP2C29 mRNA CTD PMID:19136022 phenytoin increases expression ISO RGD:734157 6480464 Phenytoin results in increased expression of CYP2C protein more ... CTD PMID:12051692 more ... phenytoin multiple interactions ISO RGD:734157 6480464 [Phenytoin results in decreased activity of CYP2C29 protein] which results in decreased reduction of and results in decreased oxidation of 9-anthraldehyde, NR1I3 protein affects the reaction [Phenytoin results in increased expression of CYP2C29 mRNA] CTD PMID:15155833 , PMID:21766881 pimecrolimus multiple interactions ISO RGD:1606589 6480464 pimecrolimus inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA] CTD PMID:29356861 pioglitazone multiple interactions ISO RGD:1606589 6480464 Gemfibrozil inhibits the reaction [CYP2C8 protein affects the metabolism of pioglitazone] CTD PMID:15900286 pioglitazone increases expression ISO RGD:1606589 6480464 Pioglitazone results in increased expression of CYP2C8 mRNA CTD PMID:31233785 pioglitazone decreases activity ISO RGD:1606589 6480464 pioglitazone results in decreased activity of CYP2C8 protein CTD PMID:12642470 pioglitazone affects metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein affects the metabolism of pioglitazone CTD PMID:15900286 piperacillin decreases activity ISO RGD:1606589 6480464 Piperacillin results in decreased activity of CYP2C8 protein CTD PMID:26763401 piperacillin multiple interactions ISO RGD:1606589 6480464 Piperacillin inhibits the reaction [CYP2C8 protein results in decreased methylation of Aminopyrine] CTD PMID:26763401 pirinixic acid multiple interactions ISO RGD:734157 6480464 [pirinixic acid co-treated with PPARA] results in decreased expression of CYP2C29 mRNA, PPARA protein affects the reaction [pirinixic acid results in decreased expression of CYP2C29 mRNA] CTD PMID:17405874 , PMID:20813756 pirinixic acid decreases expression ISO RGD:1606589 6480464 pirinixic acid results in decreased expression of CYP2C8 protein CTD PMID:29960002 pirinixic acid decreases expression ISO RGD:734157 6480464 pirinixic acid results in decreased expression of CYP2C29 mRNA CTD PMID:17405874 more ... potassium dichromate increases expression ISO RGD:734157 6480464 Potassium Dichromate results in increased expression of CYP2C29 mRNA CTD PMID:23608068 pregnenolone 16alpha-carbonitrile increases expression ISO RGD:734157 6480464 Pregnenolone Carbonitrile results in increased expression of CYP2C29 mRNA CTD PMID:28903501 probenecid multiple interactions ISO RGD:1606589 6480464 Probenecid promotes the reaction [CYP2C8 protein affects the chemical synthesis of carbamazepine epoxide], Probenecid promotes the reaction [CYP2C8 protein affects the metabolism of Carbamazepine] CTD PMID:15915352 prochloraz increases expression ISO RGD:734157 6480464 prochloraz results in increased expression of CYP2C29 protein CTD PMID:33150952 progesterone increases expression ISO RGD:1606589 6480464 Progesterone results in increased expression of CYP2C8 mRNA CTD PMID:22837389 propiconazole increases expression ISO RGD:734157 6480464 propiconazole results in increased expression of CYP2C29 mRNA CTD PMID:21278054 quercetin decreases activity ISO RGD:1606589 6480464 Quercetin results in decreased activity of CYP2C8 protein CTD PMID:15155557 more ... quercetin decreases activity ISO RGD:734157 6480464 Quercetin results in decreased activity of CYP2C29 protein CTD PMID:18420780 quercetin multiple interactions ISO RGD:1606589 6480464 [Quercetin results in decreased activity of CYP2C8 protein] which results in decreased degradation of vanoxerine more ... CTD PMID:11502731 more ... quinidine decreases activity ISO RGD:734157 6480464 Quinidine results in decreased activity of CYP2C29 protein CTD PMID:18420780 raloxifene decreases activity ISO RGD:1606589 6480464 Raloxifene Hydrochloride results in decreased activity of CYP2C8 protein CTD PMID:15601807 resveratrol affects expression EXP 6480464 resveratrol affects the expression of CYP2C29 mRNA CTD PMID:15748624 resveratrol decreases activity ISO RGD:1606589 6480464 Resveratrol results in decreased activity of CYP2C8 protein CTD PMID:30394306 resveratrol multiple interactions ISO RGD:734157 6480464 Resveratrol inhibits the reaction [titanium dioxide results in increased expression of CYP2C29 mRNA] CTD PMID:31298478 resveratrol decreases activity ISO RGD:734157 6480464 resveratrol results in decreased activity of CYP2C29 protein CTD PMID:18420780 rifampicin increases expression ISO RGD:1606589 6480464 Rifampin results in increased expression of CYP2C8 mRNA, Rifampin results in increased expression of CYP2C8 protein CTD PMID:12040753 more ... rifampicin increases expression ISO RGD:734157 6480464 Rifampin results in increased expression of CYP2C29 mRNA CTD PMID:30503582 rifampicin multiple interactions ISO RGD:1606589 6480464 [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein more ... CTD PMID:29356861 , PMID:31629065 rifampicin multiple interactions ISO RGD:734157 6480464 [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein CTD PMID:25835148 rifampicin increases activity ISO RGD:1606589 6480464 Rifampin results in increased activity of CYP2C8 protein CTD PMID:15771232 , PMID:22126990 rifampicin affects binding ISO RGD:1606589 6480464 [Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter CTD PMID:15933212 ritonavir decreases activity ISO RGD:1606589 6480464 Ritonavir results in decreased activity of CYP2C8 protein CTD PMID:15601807 Salmeterol xinafoate decreases activity ISO RGD:1606589 6480464 Salmeterol Xinafoate results in decreased activity of CYP2C8 protein CTD PMID:15601807 Salvianolic acid A decreases activity ISO RGD:1606589 6480464 salvianolic acid A results in decreased activity of CYP2C8 protein CTD PMID:29689254 Salvianolic acid C decreases activity ISO RGD:1606589 6480464 salvianolic acid C results in decreased activity of CYP2C8 protein CTD PMID:29689254 satraplatin decreases activity ISO RGD:1606589 6480464 satraplatin results in decreased activity of CYP2C8 protein CTD PMID:24882083 Senkirkine decreases expression ISO RGD:1606589 6480464 senkirkine results in decreased expression of CYP2C8 mRNA CTD PMID:26100227 silibinin decreases activity ISO RGD:1606589 6480464 Silybin results in decreased activity of CYP2C8 protein CTD PMID:28457856 silicon dioxide decreases expression ISO RGD:1606589 6480464 Silicon Dioxide analog results in decreased expression of CYP2C8 mRNA CTD PMID:25895662 silver atom affects expression ISO RGD:734157 6480464 Silver affects the expression of CYP2C29 mRNA CTD PMID:27131904 silver(0) affects expression ISO RGD:734157 6480464 Silver affects the expression of CYP2C29 mRNA CTD PMID:27131904 simvastatin decreases activity ISO RGD:1606589 6480464 Simvastatin results in decreased activity of CYP2C8 protein CTD PMID:15601807 sodium arsenite increases expression ISO RGD:734157 6480464 sodium arsenite results in increased expression of CYP2C29 mRNA CTD PMID:25065748 sodium arsenite decreases expression ISO RGD:1606589 6480464 sodium arsenite results in decreased expression of CYP2C8 mRNA CTD PMID:29301061 , PMID:34032870 sodium fluoride increases expression ISO RGD:734157 6480464 Sodium Fluoride results in increased expression of CYP2C29 mRNA CTD PMID:27862939 sorafenib decreases activity ISO RGD:1606589 6480464 Sorafenib metabolite results in decreased activity of CYP2C8 protein, Sorafenib results in decreased activity of CYP2C8 protein CTD PMID:33556367 spironolactone decreases activity ISO RGD:1606589 6480464 Spironolactone results in decreased activity of CYP2C8 protein CTD PMID:15601807 sporidesmin A affects expression ISO RGD:1606589 6480464 sporidesmin affects the expression of CYP2C8 mRNA CTD PMID:28193462 sporidesmin A multiple interactions ISO RGD:1606589 6480464 MIR21 mRNA affects the reaction [sporidesmin affects the expression of CYP2C8 mRNA] CTD PMID:28193462 Sudan I increases oxidation ISO RGD:1606589 6480464 CYP2C8 protein results in increased oxidation of 1-phenylazo-2-naphthol CTD PMID:17159775 sulfadiazine increases hydroxylation ISO RGD:1606589 6480464 CYP2C8 protein results in increased hydroxylation of Sulfadiazine CTD PMID:15843491 sulfasalazine increases expression ISO RGD:734157 6480464 Sulfasalazine results in increased expression of CYP2C29 mRNA CTD PMID:31830553 sulfinpyrazone decreases activity ISO RGD:1606589 6480464 Sulfinpyrazone results in decreased activity of CYP2C8 protein CTD PMID:12464242 Sunset Yellow FCF multiple interactions ISO RGD:1606589 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C8 mRNA CTD PMID:33819548 tamoxifen decreases activity ISO RGD:1606589 6480464 Tamoxifen results in decreased activity of CYP2C8 protein CTD PMID:15601807 , PMID:29285606 tamoxifen multiple interactions ISO RGD:734157 6480464 [Carbon Tetrachloride co-treated with Tamoxifen] affects the expression of CYP2C29 mRNA CTD PMID:29974145 tamoxifen increases activity ISO RGD:1606589 6480464 Tamoxifen metabolite results in increased activity of CYP2C8 protein CTD PMID:29285606 tamoxifen decreases activity ISO RGD:734157 6480464 Tamoxifen results in decreased activity of CYP2C29 protein CTD PMID:18420780 Tanshinone I decreases activity ISO RGD:1606589 6480464 tanshinone results in decreased activity of CYP2C8 protein CTD PMID:29689254 testosterone decreases activity ISO RGD:734157 6480464 Testosterone results in decreased activity of CYP2C29 protein CTD PMID:18420780 tetrachloroethene increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of Tetrachloroethylene CTD PMID:11684365 tetrachloromethane multiple interactions ISO RGD:734157 6480464 [Carbon Tetrachloride co-treated with Tamoxifen] affects the expression of CYP2C29 mRNA CTD PMID:29974145 tetrachloromethane decreases expression ISO RGD:734157 6480464 Carbon Tetrachloride results in decreased expression of CYP2C29 mRNA CTD PMID:31919559 tetrahydrocurcumin multiple interactions ISO RGD:734157 6480464 tetrahydrocurcumin inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of CYP2C29 mRNA], tetrahydrocurcumin inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of CYP2C29 protein] CTD PMID:26102010 thiacloprid multiple interactions ISO RGD:734157 6480464 [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2C29 mRNA CTD PMID:32745781 Thiocoraline affects metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein affects the metabolism of thiocoraline CTD PMID:15122071 thiophanate-methyl multiple interactions ISO RGD:734157 6480464 [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2C29 mRNA CTD PMID:32745781 thyroxine decreases activity ISO RGD:1606589 6480464 Thyroxine results in decreased activity of CYP2C8 protein CTD PMID:15601807 ticlopidine multiple interactions ISO RGD:1606589 6480464 CYP2C8 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite CTD PMID:19170597 titanium dioxide increases expression ISO RGD:734157 6480464 titanium dioxide results in increased expression of CYP2C29 mRNA CTD PMID:31298478 titanium dioxide multiple interactions ISO RGD:734157 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C29 mRNA, Resveratrol inhibits the reaction [titanium dioxide results in increased expression of CYP2C29 mRNA] CTD PMID:29950665 , PMID:31298478 tolbutamide increases hydroxylation ISO RGD:1606589 6480464 CYP2C8 protein results in increased hydroxylation of Tolbutamide CTD PMID:15843491 torasemide multiple interactions ISO RGD:1606589 6480464 Torsemide inhibits the reaction [Amiodarone results in decreased activity of CYP2C8 protein] more ... CTD PMID:15304522 torasemide increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of Torsemide CTD PMID:15304522 trans-cinnamic acid decreases activity ISO RGD:1606589 6480464 cinnamic acid analog results in decreased activity of CYP2C8 protein CTD PMID:15072549 tranylcypromine multiple interactions ISO RGD:1606589 6480464 Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:24120545 triadimefon decreases expression ISO RGD:734157 6480464 triadimefon results in decreased expression of CYP2C29 mRNA CTD PMID:16730040 triflumuron increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of triflumuron CTD PMID:31082524 trimethoprim increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of Trimethoprim CTD PMID:12464242 trimethoprim decreases activity ISO RGD:1606589 6480464 Trimethoprim results in decreased activity of CYP2C8 protein CTD PMID:15570183 Triptolide decreases expression ISO RGD:734157 6480464 triptolide results in decreased expression of CYP2C29 mRNA CTD PMID:32835833 Triptolide decreases expression EXP 6480464 triptolide results in decreased expression of CYP2C8 protein CTD PMID:33600922 troglitazone increases expression ISO RGD:734157 6480464 troglitazone results in increased expression of CYP2C8 mRNA CTD PMID:28973697 troglitazone increases expression ISO RGD:1606589 6480464 troglitazone results in increased expression of CYP2C8 mRNA CTD PMID:25572481 troglitazone increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of troglitazone CTD PMID:19356091 troglitazone decreases activity ISO RGD:1606589 6480464 troglitazone results in decreased activity of CYP2C8 protein CTD PMID:12642470 tryptamines multiple interactions ISO RGD:1606589 6480464 [Tryptamines analog results in decreased activity of CYP2C8 protein] which results in decreased metabolism of Amodiaquine CTD PMID:26599973 tryptamines decreases activity ISO RGD:1606589 6480464 Tryptamines analog results in decreased activity of CYP2C8 protein CTD PMID:26599973 valproic acid decreases expression ISO RGD:1606589 6480464 Valproic Acid results in decreased expression of CYP2C8 mRNA CTD PMID:29501571 vanoxerine dihydrochloride decreases degradation ISO RGD:1606589 6480464 CYP2C8 protein results in decreased degradation of vanoxerine CTD PMID:11502731 vanoxerine dihydrochloride multiple interactions ISO RGD:1606589 6480464 [Quercetin results in decreased activity of CYP2C8 protein] which results in decreased degradation of vanoxerine CTD PMID:11502731 verapamil multiple interactions ISO RGD:1606589 6480464 torsemide inhibits the reaction [Verapamil results in decreased activity of CYP2C8 protein] CTD PMID:15304522 verapamil decreases activity ISO RGD:734157 6480464 Verapamil results in decreased activity of CYP2C29 protein CTD PMID:18420780 verapamil decreases activity ISO RGD:1606589 6480464 Verapamil results in decreased activity of CYP2C8 protein CTD PMID:15304522 vincristine increases response to substance ISO RGD:1606589 6480464 CYP2C8 gene SNP results in increased susceptibility to Vincristine CTD PMID:21245421 warfarin decreases activity ISO RGD:734157 6480464 Warfarin results in decreased activity of CYP2C29 protein CTD PMID:18420780 zafirlukast decreases activity ISO RGD:1606589 6480464 zafirlukast results in decreased activity of CYP2C8 protein CTD PMID:15601807 ziram multiple interactions ISO RGD:734157 6480464 [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2C29 mRNA CTD PMID:32745781 zopiclone increases metabolic processing ISO RGD:1606589 6480464 CYP2C8 protein results in increased metabolism of zopiclone CTD PMID:12464242
